CRON vs. USNA, CGC, MNMD, BTMD, ACB, CDXC, CNTA, MDXG, INVA, and ALHC
Should you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include USANA Health Sciences (USNA), Canopy Growth (CGC), Mind Medicine (MindMed) (MNMD), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), Centessa Pharmaceuticals (CNTA), MiMedx Group (MDXG), Innoviva (INVA), and Alignment Healthcare (ALHC). These companies are all part of the "medical" sector.
Cronos Group (NASDAQ:CRON) and USANA Health Sciences (NYSE:USNA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
Cronos Group has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.
USANA Health Sciences has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are owned by institutional investors. 2.0% of Cronos Group shares are owned by insiders. Comparatively, 0.3% of USANA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
USANA Health Sciences has a net margin of 6.93% compared to Cronos Group's net margin of -84.15%. USANA Health Sciences' return on equity of 13.49% beat Cronos Group's return on equity.
In the previous week, Cronos Group and Cronos Group both had 4 articles in the media. Cronos Group's average media sentiment score of 0.76 beat USANA Health Sciences' score of 0.00 indicating that Cronos Group is being referred to more favorably in the media.
Cronos Group currently has a consensus target price of $2.83, indicating a potential upside of 12.88%. USANA Health Sciences has a consensus target price of $48.00, indicating a potential upside of 9.84%. Given Cronos Group's higher probable upside, equities research analysts clearly believe Cronos Group is more favorable than USANA Health Sciences.
Cronos Group received 69 more outperform votes than USANA Health Sciences when rated by MarketBeat users. Likewise, 61.21% of users gave Cronos Group an outperform vote while only 60.77% of users gave USANA Health Sciences an outperform vote.
Summary
USANA Health Sciences beats Cronos Group on 9 of the 17 factors compared between the two stocks.
Get Cronos Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cronos Group Competitors List
Related Companies and Tools
